Indian stock markets are expected to witness stock-specific action on Wednesday, July 16, as a series of corporate developments, quarterly earnings, and regulatory updates come into play.
Stocks to Watch – July 16, 2025
-
Biocon – USFDA nod for insulin biosimilar to Novolog
-
CFF Fluid Control – MoU signed with GRSE
-
Lemon Tree Hotels – Opens 6th property in Tamil Nadu (Erode)
-
Aris Infra – MoU with Wadhwa Construction for Panvel project
-
20 Microns – Stake increased by Dolly Khanna in Q1
-
Godavari Biorefineries – Patent granted for cancer treatment compound
-
Hathway Cable – Strong YoY growth in net profit and revenue
-
HSCL – Improved quarterly earnings
-
ICICI Lombard – Sharp rise in profit and NPE
-
Brigade Enterprises – BuzzWorks expands in Hyderabad
-
Spandana Sphoorty – ₹400 crore rights issue announced
-
Zydus Lifesciences – USFDA approval for Celecoxib capsules
-
ICICI Bank – S&P revises credit profile upward
-
Cupid – Investment in GII Healthcare to expand in Middle East
-
Thirumalai Chemicals – Reports construction progress in US unit
-
KPI Green – LOI received for 150 MW wind power projects in Gujarat
-
Pavna Industries – Wins new OEM business for switches & latches
-
Axis Bank – Ratings reaffirmed by Crisil
-
Dixon Technologies – To acquire 51% stake in Q Tech India
-
HDFC Life – Net profit rises YoY
-
TCS – Launches AI research series with MIT Sloan
-
Just Dial – Higher YoY profit and revenue
-
Adani Ports – Approves $200 million debt buyback plan
-
Yes Bank – Board to meet July 19 for fundraising proposal
-
IndiGo – Appoints new independent director
-
PVR Inox – Karnataka government proposes ticket price cap
-
MTNL – Defaults on ₹8,585 crore in loans and interest
-
Patel Engineering – Court dismisses appeal in arbitration case
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
